ArticleNature communications2025
Development and application of GlycanDIA workflow for glycomic analysis.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The 'sugar' side of extracellular vesicle-glycome: a panorama from basic characteristics, deciphering technologies, functions, to applications.Journal of nanobiotechnology · 2026Review
- Glycan Sequencing, A Brief Primer.Glycoscience & therapy · 2026Article
- AquIRE reveals the mechanisms of clinically induced RNA damage and the conservation and dynamics of glycoRNAs.Nucleic acids research · 2026Article
- GlycoRNA research: from unknown unknowns to known unknowns.Protein & cell · 2026Review
- Functional regulation of GlycoRNA and progress in malignant tumors.Journal of translational medicine · 2026Review
- GlycoRNAdb: a database of glycoRNA sequences, structures, abundance, and glycan information across tissues and cell lines.Nucleic acids research · 2026Article
- GlycoRNA in cancer immune regulation and progression: biological mechanisms and translational therapeutic prospects.Frontiers in immunology · 2026Review
- Natural polysaccharides as immune adjuvants to overcome immune checkpoint inhibitor resistance: mechanistic insights, clinical evidence, and translational challenges.Frontiers in immunology · 2026Review
- O-glycosylation in Cancer: Emerging Paradigms and Prospects for Precision Oncology.International journal of biological sciences · 2026Review
- Cell surface RNAs define a new interface for immune recognition.Frontiers in immunology · 2026Review
- Article
- Absolute Quantitation of Phosphopeptides and Glycopeptides Using Coulometric Mass Spectrometry.ACS measurement science au · 2025Article
- Robust and High-Resolution All-Ion Fragmentation LC-ESI-IM-MS Analysis for In-Depth Characterization or Profiling of Up to 200 Human Milk Oligosaccharides.Analytical chemistry · 2025Article
- Recent Advances in Labeling-Based Quantitative Glycomics: From High-Throughput Quantification to Structural Elucidation.Proteomics · 2025Review
- The modified RNA base acpCell · 2024Article
- O-glycosylation contributes to mammalian glycoRNA biogenesis.bioRxiv : the preprint server for biology · 2024Article
- Mass Spectrometry Analysis of Nucleic Acid Modifications: From Beginning to Future.Mass spectrometry reviewsReview
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
Glycans modify protein, lipid, and even RNA molecules to form the regulatory outer coat on cells called the glycocalyx. The changes in glycosylation have been linked to the initiation and progression of many diseases. Herein, we report a DIA-based glycomic workflow, termed GlycanDIA, to identify and quantify glycans with high sensitivity and precision. The GlycanDIA workflow combines higher energy collisional dissociation (HCD)-MS/MS and staggered windows for glycomic analysis, which facilitates the sensitivity in identification and precision in quantification compared to conventional glycomic methods. To facilitate its use, we also develop a generic search engine, GlycanDIA Finder, incorporating an iterative decoy searching for confident glycan identification from DIA data. Our results demonstrate that GlycanDIA can distinguish glycan composition and isomers from N-glycans, O-glycans, and human milk oligosaccharides (HMOs), while it also reveals information on low-abundant modified glycans. With the improved sensitivity and precision, we perform experiments to profile N-glycans from RNA samples, which have been underrepresented due to their low abundance. Using this integrative workflow to unravel the N-glycan profile in cellular and tissue glycoRNA samples, we find that RNA-glycans have different abundant forms as compared to protein-glycans and there are also tissue-specific differences, suggesting their distinct functions in biological processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.